CHMP gives positive opinion on Genmab partner's lung cancer drug
![Photo: Tuala Hjarnø / Genmab / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13375966.ece/ALTERNATES/schema-16_9/doc7hzcb0vgu6v8tmfy79y.jpg)
Genmab's US partner, Janssen, has received a positive opinion from the CHMP, a committee that is part of the European Medicines Agency, and a recommendation that its candidate receives conditional marketing authorization in Europe for the treatment of non-small cell lung cancer. The dug is called amivantamab, with the commercial name Rybrevant.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Janssen is foreign company of the year in Denmark
For subscribers
New Genmab/Seagen drug will cost up to USD 120,000
For subscribers
Analyst: New Genmab approval shows portfolio potential
For subscribers